Continued EryDex treatment studied in rare neurological disorder
NCT ID NCT06664853
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (a rare genetic disease affecting coordination and immunity) who had finished a previous trial. The main goal was to track safety, such as side effects. The study was terminated early, and no new treatment benefits were measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital, Division of neurology
Cincinnati, Ohio, 45229, United States
-
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
Copenhagen, Denmark, 2100, Denmark
-
Great Ormond Street Hospital for Children, Zayed Centre for Research
London, United Kingdom, WC1N 1DZ, United Kingdom
-
Hospital Universitari Vall d'Hebron, Department of pediatric neurology
Barcelona, Spain, 08035, Spain
-
Hospital Universitario La Paz, Department of pediatric neurology
Madrid, Spain, 28046, Spain
-
IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
Frankfurt am Main, Hesse, 60596, Germany
-
Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
Warsaw, 04-736, Poland
-
MedPolonia sp zoo
Poznan, 60-693, Poland
-
Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
Nottingham, United Kingdom, NG7 2UH, United Kingdom
-
Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
Oslo, Norway, 0372, Norway
-
Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
Roma, Italy, 00161, Italy
-
Saint Peter's University Hospital, Inc.
New Brunswick, New Jersey, 08901, United States
-
Spedali Civili di Brescia, Pediatric immunology department
Brescia, Italy, 25213, Italy
-
St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
London, SE1 7EH, United Kingdom
-
The Johns Hopkins Hospital, Division of pediatric allergy and immunology
Baltimore, Maryland, 21289, United States
-
UT Health Houston, Department of pediatrics, division of child & adolescent neurology
Houston, Texas, 77030, United States
-
Universitary Hospital Virgen del Rocío
Seville, 41013, Spain
-
University Children's Hospital Zürich - Eleonore Foundation
Zurich, CH 8008, Switzerland
-
University Hospital Frankfurt, Pediatric and Adolescent Clinic
Frankfurt, Germany, 60590, Germany
-
University Hospitals Birmingham NHS Foundation Trust
Birmingham, B152GW, United Kingdom
-
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.